Spyre Therapeutics (FRA:3920) EBIT: €-207.75 Mil (TTM As of Mar. 2026)


FRA:3920 Spyre Therapeutics Inc FRA:3920
33 GF Score
Price €77.00
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics EBIT?

Spyre Therapeutics FRA:3920 +0.65% 33 EBIT is €-207.75 Mil as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

Spyre Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-65.43 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-207.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Spyre Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -704.67%. Spyre Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Spyre Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.36%.

Spyre Therapeutics  (FRA:3920) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Spyre Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-261.716 * ( 1 - 0% )/( (26.422 + 47.858)/ 2 )
=-261.716/37.14
=-704.67 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=664.225 - 23.695 - ( 646.079 - max(0, 50.117 - 664.225+646.079))
=26.422

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=660.819 - 25.807 - ( 641.369 - max(0, 73.665 - 660.819+641.369))
=47.858

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Spyre Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-261.716/( ( (0 + max(-31.971, 0)) + (0 + max(-54.215, 0)) )/ 2 )
=-261.716/( ( 0 + 0 )/ 2 )
=-261.716/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 18.146) - (23.695 + 0 + 26.422)
=-31.971

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 19.45) - (25.807 + 0 + 47.858)
=-54.215

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Spyre Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-207.751/6176.554
=-3.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics EBIT Related Terms

Spyre Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics EBIT Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.10 -80.03 -117.89 -199.18 -187.51

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.55 -45.03 -48.47 -48.83 -65.43

FRA:3920 vs PTGX, CELC, MIRM: EBIT Comparison

For the Biotechnology subindustry, Spyre Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's EV-to-EBIT falls into.


FRA:3920
33GF Score
Spyre Therapeutics Inc FRA:3920
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-207.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-207.75 Mil mean?
Spyre Therapeutics (FRA:3920) has a EBIT of €-207.75 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Spyre Therapeutics.
Is Spyre Therapeutics' EBIT too high?
Spyre Therapeutics' current EBIT is €-207.75 Mil. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' EBIT compare to PTGX and CELC?
Spyre Therapeutics' EBIT of €-207.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Spyre Therapeutics. Spyre Therapeutics's current EBIT is €-207.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current EBIT of €-207.75 Mil. The current EBIT is €-207.75 Mil. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current EBIT is €-207.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score

Get the complete analysis for FRA:3920

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price